WP
PAVM icon

WealthPLAN Partners’s PAVmed PAVM Stock Holding History

WealthPLAN Partners’s Portfolio PAVM Stock Details PAVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-72
Closed -$9.53K – 337
2023
Q3 		$9.53K Buy
72
+11
+18% +$1.71K ﹤0.01% 315
2023
Q2 		$11.1K Sell
61
-11
-15% -$2.2K ﹤0.01% 779
2023
Q1 		$12.1K Hold
72
– – ﹤0.01% 820
2022
Q4 		$13.3K Buy
+72
New +$27.2K ﹤0.01% 392
2022
Q1 		$36K Buy
64
+3
+5% +$2.23K ﹤0.01% 378
2021
Q4 		$47K Buy
61
+1
+2% +$2.17K ﹤0.01% 377
2021
Q3 		$94K Sell
60
-35
-37% -$110K 0.01% 369
2021
Q2 		$297K Hold
95
– – 0.02% 292
2021
Q1 		$190K Buy
95
+17
+22% +$25.6K 0.01% 322
2020
Q4 		$77K Hold
78
– – 0.01% 327
2020
Q3 		$63K Hold
78
– – 0.01% 309
2020
Q2 		$76K Hold
78
– – 0.01% 302
2020
Q1 		$79K Buy
+78
New +$63.8K 0.01% 246

Other funds holding PAVM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
XF
XML Financial Bethesda, Maryland $1.37B AUM 28.49% 1-Year Est. Return

WealthPLAN Partners's PAVM Position: Q4 2023 in Review

WealthPLAN Partners sold out of PAVmed (PAVM) in Q4 2023, closing a stake of 72 shares — an estimated $9.53K sold.

WealthPLAN Partners first reported a position in PAVM in Q1 2020 and held it in 13 quarters. The position peaked at $297K in Q2 2021. 23 funds tracked by Wall St. Rank hold PAVM as of Q4 2023.

  • WealthPLAN Partners reported no remaining PAVmed position as of Q4 2023 after selling out during the quarter.
  • WealthPLAN Partners sold 72 PAVmed shares in Q4 2023, an estimated $9.53K.
  • WealthPLAN Partners first reported a position in PAVmed in Q1 2020 and held it in 13 quarters.
  • WealthPLAN Partners's PAVmed position peaked at $297K in Q2 2021.
  • 23 funds tracked by Wall St. Rank held PAVmed as of Q4 2023.

Based on WealthPLAN Partners's 13F filing for Q4 2023, filed 5 Jan 2024.